Novavax (NVAX)
(Delayed Data from NSDQ)
$12.32 USD
-0.31 (-2.45%)
Updated Oct 1, 2024 04:00 PM ET
Pre-Market: $12.26 -0.06 (-0.49%) 8:28 AM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$12.32 USD
-0.31 (-2.45%)
Updated Oct 1, 2024 04:00 PM ET
Pre-Market: $12.26 -0.06 (-0.49%) 8:28 AM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Zacks News
Novavax Begins Phase III Study on Coronavirus Vaccine in the UK
by Zacks Equity Research
Novavax (NVAX) starts a phase III efficacy study on its COVID-19 vaccine candidate NVX-CoV2373 in the United Kingdom. Stock rises in after-hours trading.
Rollercoaster Market for Thursday
by Mark Vickery
The major indexes gained less than 1% in total Thursday: +0.37% on the Nasdaq, +0.30% on the S&P 500, +0.20% on the Dow and +0.02% for the Russell 2000.
The Zacks Analyst Blog Highlights: NVAX, MRNA, VIR and BNTX
by Zacks Equity Research
The Zacks Analyst Blog Highlights: NVAX, MRNA, VIR and BNTX
4 Biotechs That Have More Than Doubled Thanks to Coronavirus
by Kinjel Shah
Stocks of several small biotech companies more than double so far this year as they taste success in their efforts to make a vaccine/medicine for treating COVID-19.
Novavax (NVAX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed the most recent trading day at $110.15, moving +1.65% from the previous trading session.
Novavax Expands Coronavirus Vaccine Manufacturing Deal in India
by Zacks Equity Research
Novavax (NVAX) amends its present contract with Serum Institute of India Private Limited to widen the manufacturing capacity of its COVID-19 vaccine candidate NVX-CoV2373 to 2 billion plus doses in 2021.
Vaxart Gets FDA Nod for Phase I Study on Coronavirus Vaccine
by Zacks Equity Research
Vaxart's (VXRT) investigational new drug application for oral coronavirus vaccine candidate gets a clearance from the FDA. The company will begin a phase I study later this month.
Why Is Novavax (NVAX) Down 42.9% Since Last Earnings Report?
by Zacks Equity Research
Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Coronavirus Vaccine Efforts Hit as AstraZeneca Halts Study
by Kinjel Shah
Amid rising optimism on timely approval of a safe vaccine, the vaccine development efforts of AstraZeneca (AZN) have hit a roadblock.
Implied Volatility Surging for Novavax (NVAX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.
Novavax to Supply Coronavirus Vaccine to Canadian Government
by Zacks Equity Research
Novavax (NVAX) signs a contract with the Government of Canada for supplying up to 76 million doses of its COVID-19 vaccine NVX-CoV2373, if approved.
Biotech Stock Roundup: BMY to Buy Forbius, BMRN Gets CRL & Other Updates
by Zacks Equity Research
The biotech sector remains in focus with drug approvals, and regulatory and other pipeline updates.
5 Sectors Set to Boom on Coronavirus Vaccine Optimism: Top Picks
by Sweta Killa
While the prospect of a COVID-19 treatment will lead to broad-based gains, some investing areas are expected to benefit the most.
The Zacks Analyst Blog Highlights: Emergent Biosolutions, Horizon, Novavax, Celldex and Aileron Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Emergent Biosolutions, Horizon, Novavax, Celldex and Aileron Therapeutics
Novavax Begins Enrollment in Phase II Coronavirus Vaccine Study
by Zacks Equity Research
Novavax (NVAX) starts enrolling in the phase II portion of its COVID-19 vaccine study, which is testing the immunogenicity and safety of its candidate NVX-CoV2373 in the United States and Australia.
Is Novavax (NVAX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (NVAX) Outperforming Other Medical Stocks This Year?
5 Biotech Stocks Up More Than 100% This Year So Far
by Zacks Equity Research
Here we discuss five biotech companies recording impressive growth so far in 2020.
Biotech Stock Roundup: GILD Gets CRL, REGN Collaborates With RHHBY & More
by Zacks Equity Research
The biotech sector remains in focus with regulatory and other pipeline updates.
Novavax Begins Phase IIb Coronavirus Vaccine Study in South Africa
by Zacks Equity Research
Novavax (NVAX) starts a phase IIb study in South Africa to evaluate the efficacy of its COVID-19 vaccine candidate NVX-CoV2373. Shares rise following this development.
Company News for Aug 18, 2020
by Zacks Equity Research
Companies In The News Are: DPZ, NVAX, JD, CRTX.
Company News for Aug 17, 2020
by Zacks Equity Research
Companies in the news are: AMAT, MESO, NVAX, SKYS
Encompass Health's Buyout Spree on Track, PPE Costs High
by Zacks Equity Research
Encompass Health (EHC) continues to benefit from buyouts and cash generating abilities. However, increased PPE utilization is worrisome.
Novavax (NVAX) to Supply Coronavirus Vaccine to UK Government
by Zacks Equity Research
Novavax (NVAX) enters an agreement to provide the UK government with 60 million doses of its COVID-19 vaccine, NVX-CoV2373, if approved.
FUJIFILM (FUJIY) Q1 Earnings Top Estimates, Revenues Drop Y/Y
by Zacks Equity Research
FUJIFILM's (FUJIY) fiscal first-quarter results reflect coronavirus impact on the top line and operating income.
Should You Invest in COVID Themed ETFs?
by Neena Mishra
We highlight three new ETFs that seek to capitalize on coronavirus